Published in J Immunol on October 01, 2005
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol (2011) 2.05
Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury. J Clin Invest (2012) 2.00
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology (2010) 1.69
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol (2007) 1.68
Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia (2008) 1.43
Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med (2015) 1.42
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem (2010) 1.25
Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J (2008) 1.16
The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol (2013) 1.06
Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol (2012) 1.01
The roles of CD73 in cancer. Biomed Res Int (2014) 1.01
Growth factor regulation of prostaglandin-endoperoxide synthase 2 (Ptgs2) expression in colonic mesenchymal stem cells. J Biol Chem (2009) 1.00
Adenosine 2A receptor antagonist prevented and reversed liver fibrosis in a mouse model of ethanol-exacerbated liver fibrosis. PLoS One (2013) 0.95
CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunology (2012) 0.94
Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother (2010) 0.92
Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors. J Immunol (2014) 0.89
Adenosine and lymphocyte regulation. Purinergic Signal (2007) 0.88
Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal (2012) 0.88
Targeting regulatory T cells to improve vaccine immunogenicity in early life. Front Microbiol (2014) 0.88
Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8(+) T-cell priming capacity. Immunology (2013) 0.87
Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J Mol Med (Berl) (2013) 0.87
Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression. Brain Behav Immun (2010) 0.84
In vitro atrazine-exposure inhibits human natural killer cell lytic granule release. Toxicol Appl Pharmacol (2007) 0.81
P1 receptors and cytokine secretion. Purinergic Signal (2007) 0.80
p73 engages A2B receptor signalling to prime cancer cells to chemotherapy-induced death. Oncogene (2015) 0.80
Adenosine and immune imbalance in visceral leishmaniasis: the possible role of ectonucleotidases. J Trop Med (2011) 0.80
Immune profiling and cancer post transplantation. World J Nephrol (2015) 0.77
The immunosuppressive role of adenosine A2A receptors in ischemia reperfusion injury and islet transplantation. Curr Diabetes Rev (2012) 0.77
High homocysteine levels prevent via H2 S the CoCl2 -induced alteration of lymphocyte viability. J Cell Mol Med (2016) 0.75
Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer (2017) 0.75
A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25
Animal models of sepsis: setting the stage. Nat Rev Drug Discov (2005) 3.63
Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One (2008) 3.36
Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol (2010) 2.71
Concern Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest (2012) 2.23
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15
Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol (2006) 1.93
Sex hormones and hypertension. Cardiovasc Res (2002) 1.74
Blast exposure in rats with body shielding is characterized primarily by diffuse axonal injury. J Neurotrauma (2011) 1.71
2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res (2006) 1.70
Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood (2013) 1.70
Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods (2009) 1.69
Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 1.66
Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res (2005) 1.51
Requirements for T lymphocyte migration in explanted lymph nodes. J Immunol (2007) 1.48
Recombination of retrotransposon and exogenous RNA virus results in nonretroviral cDNA integration. Science (2009) 1.47
Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol (2004) 1.45
Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol (2006) 1.41
Conversion of tibolone to 7alpha-methyl-ethinyl estradiol using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry: interpretation and clinical implications. Menopause (2006) 1.38
Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab (2006) 1.37
A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J Immunol (2011) 1.36
Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: effects of moderate hypothermia. J Neurotrauma (2007) 1.34
Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res (2009) 1.28
A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol (2009) 1.27
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem (2010) 1.25
Three-dimensional localization of serine 2808, a phosphorylation site in cardiac ryanodine receptor. J Biol Chem (2007) 1.24
Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res (2007) 1.20
Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol (2007) 1.20
Adenosine A2a receptors induce heterologous desensitization of chemokine receptors. Blood (2006) 1.19
Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther (2003) 1.18
The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol (2012) 1.18
2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol (2006) 1.17
Aspects of the general biology of adenosine A2A signaling. Prog Neurobiol (2007) 1.17
Assessment of nerve stimulation-induced release of purines from mouse kidneys by tandem mass spectrometry. J Pharmacol Exp Ther (2008) 1.17
Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res (2002) 1.16
Identification and quantification of 2',3'-cAMP release by the kidney. J Pharmacol Exp Ther (2008) 1.14
cAMP-adenosine pathway in the proximal tubule. J Pharmacol Exp Ther (2006) 1.13
Biological significance of prolactin in gynecologic cancers. Cancer Res (2009) 1.13
Complexities of oestradiol pharmacology in pulmonary arterial hypertension. Eur Respir J (2013) 1.11
Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer (2008) 1.11
Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol Immunother (2008) 1.08
Adenosine receptor expression and function in bladder uroepithelium. Am J Physiol Cell Physiol (2006) 1.07
Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol Metab (2009) 1.07
Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: effect on biochemical markers. J Neurotrauma (2004) 1.07
1,3,7-trimethylxanthine (caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological immunosuppressive mechanism. J Immunol (2007) 1.04
Adenosine A1 receptor activation as a brake on the microglial response after experimental traumatic brain injury in mice. J Neurotrauma (2010) 1.04
Nonresolving inflammation in gp91phox-/- mice, a model of human chronic granulomatous disease, has lower adenosine and cyclic adenosine 5'-monophosphate. J Immunol (2009) 1.03
Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells. Cancer Res (2006) 1.03
DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis (2012) 1.01
Role of eotaxin-1 signaling in ovarian cancer. Clin Cancer Res (2009) 1.01
Screening of biochemical and molecular mechanisms of secondary injury and repair in the brain after experimental blast-induced traumatic brain injury in rats. J Neurotrauma (2013) 0.99
Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol (2005) 0.99
A(2B) adenosine receptors stimulate growth of porcine and rat arterial endothelial cells. Hypertension (2002) 0.98
Sphingosine-1-phosphate reduces CD4+ T-cell activation in type 1 diabetes through regulation of hypoxia-inducible factor short isoform I.1 and CD69. Diabetes (2007) 0.97
Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler Thromb Vasc Biol (2012) 0.96
Murine orthostatic response during prolonged vertical studies: effect on cerebral blood flow measured by arterial spin-labeled MRI. Magn Reson Med (2005) 0.96
The A2aR adenosine receptor controls cytokine production in iNKT cells. Eur J Immunol (2010) 0.96
Alpha2-adrenoceptors enhance angiotensin II-induced renal vasoconstriction: role for NADPH oxidase and RhoA. Hypertension (2008) 0.96
Adenosine negative feedback on A2A adenosine receptors mediates hyporesponsiveness in chronically septic mice. Shock (2011) 0.96
Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection. Hypertension (2010) 0.96
Expression of the 2',3'-cAMP-adenosine pathway in astrocytes and microglia. J Neurochem (2011) 0.95
Pancreatic polypeptide-fold peptide receptors and angiotensin II-induced renal vasoconstriction. Hypertension (2005) 0.94
CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension (2002) 0.94
CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunology (2012) 0.94
Extracellular 3',5'-cAMP-adenosine pathway inhibits glomerular mesangial cell growth. J Pharmacol Exp Ther (2010) 0.94
Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection. J Mol Med (Berl) (2014) 0.94
Vascular endothelial growth factor is increased in cerebrospinal fluid after traumatic brain injury in infants and children. Neurosurgery (2004) 0.93
2-Methoxyestradiol: a potential treatment for multiple proliferative disorders. Endocrinology (2007) 0.93
A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX-LC-MS/MS. Mol Cell Biochem (2010) 0.93
Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production. Exp Cell Res (2008) 0.93
Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev (2006) 0.93
Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol (2010) 0.93
2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats. J Cardiovasc Pharmacol (2007) 0.93
Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol (2013) 0.92
Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension (2004) 0.92
alpha 2-Adrenoceptors potentiate angiotensin II- and vasopressin-induced renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther (2003) 0.92
Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension (2002) 0.92
Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother (2010) 0.92
Adenosine inhibits PDGF-induced growth of human glomerular mesangial cells via A(2B) receptors. Hypertension (2005) 0.92
Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. Bioorg Med Chem Lett (2010) 0.92